It is very uncertain whether PERPHENAZINE changes global state: Change over time ‐ no better or deterioration ‐ short… compared with PLACEBO (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether PERPHENAZINE changes adverse events: extrapyramidal adverse effects dystonia ‐ short term compared with ANY ANTIPSYCHOTICS (very low certainty).
It is very uncertain whether PERPHENAZINE changes other adverse events: any serious adverse event ‐ short and long term compared with ANY ANTIPSYCHOTICS (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether PERPHENAZINE changes mental state: Relapse ‐ short term clinical diagnosis compared with PLACEBO (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether PERPHENAZINE changes adverse events: extrapyramidal adverse effects ‐ dystonia ‐ short term compared with PLACEBO (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether PERPHENAZINE changes global state: Change over time ‐ no better or deterioration ‐ short… compared with ANY ANTIPSYCHOTICS (very low certainty).
It is very uncertain whether PERPHENAZINE changes mental state: State ‐ 'no effect' BPRS score reduction compared with ANY ANTIPSYCHOTICS (very low certainty).
Comparison 1: PERPHENAZINE showed no clear difference in response to treatment compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (moderate certainty).
It is very uncertain whether comparison 1: PERPHENAZINE changes acceptability of treatment ‐ leaving the study early due to any reason compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (very low certainty).
Comparison 1: PERPHENAZINE showed no clear difference in adverse effects ‐ at least one adverse effect compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).
Comparison 1: PERPHENAZINE showed no clear difference in adverse effects ‐ movement disorders ‐ at least one movement disorder compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).
Comparison 1: PERPHENAZINE showed no clear difference in death compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (moderate certainty).